Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 63 Carcinoma, Hepatocellular 55 Lung Neoplasms 32 Breast Neoplasms 29 Small Cell Lung Carcinoma 23 Neoplasms 21 Triple Negative Breast Neoplasms 18 Neoplasm Metastasis 17 Urinary Bladder Neoplasms 15 Carcinoma, Transitional Cell 15 Melanoma 14 Colorectal Neoplasms 14 Glioblastoma 10 Prostatic Neoplasms 9 Ovarian Neoplasms 9 Head and Neck Neoplasms 9 Recurrence 8 Liver Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Renal Cell 8 Mesothelioma, Malignant 7 Uterine Cervical Neoplasms 6 Sarcoma 6 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Rectal Neoplasms 5 Kidney Neoplasms 5 Gastrointestinal Neoplasms 5 Carcinoma, Squamous Cell 5 Pancreatic Neoplasms 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × atezolizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡